Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, GENFIT has gained the exclusive worldwide rights of SRT-015, a highly optimized, first-in-class ASK1 inhibitor being developed in acute-on-chronic liver failure (ACLF), from Seal Rock Therapeutics.
Lead Product(s): SRT-015
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: SRT-015
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Genfit
Deal Size: $106.8 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 31, 2023
Details:
SRT-015 is a second generation apoptosis signal-regulating kinase (ASK1) inhibitor for treatment of alcoholic hepatitis, non-alcoholic steatohepatitis (NASH) and other liver diseases.
Lead Product(s): SRT-015
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: SRT-015
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
The presentations demonstrate superior pharmacological properties of SRT-015 compared to other ASK1 inhibitors, including selonsertib, and provide potential explanations for the failure of selonsertib in clinical trials.
Lead Product(s): SRT-015
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: SRT-015
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
Posters to highlight excellent efficacy of SRT-015 in NASH-relevant models, and comparator data with the ASK1 inhibitor selonsertib that is consistent with its lack of efficacy in phase 3 trials.
Lead Product(s): SRT-015
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: SRT-015
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020